InsidersTradesSigma
Total declarations
Companies
▲ Purchases (18 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
18
Disclosed sells
0
T+90 hit rate
67%
T+90 mean return
+6.2%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Heron Patrick J, Director. Insider active across 4 companies, notably Imago BioSciences, Inc.. Cumulatively, 23 reports have been published. Breakdown: 18 buys · 0 sell. Total volume traded: €5.6m. History available since 20 July 2021. The latest transaction was filed on 5 June 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations23 total
5,778 shares0Common StockSEC:0001628280-26-042046:0
2,646 shares@ US$13.08037.8% of flowCommon StockSEC:0001415889-25-017576:0
Ideal exit: 10 Mar 2026 (T+270)
2,520 shares@ US$13.668.0% of flowCommon StockSEC:0001415889-25-014415:0
Ideal exit: 15 Feb 2026 (T+270)
2,520 shares@ US$13.61788.1% of flowCommon StockSEC:0001415889-25-013620:0
Ideal exit: 9 Feb 2026 (T+270)
2,374 shares@ US$13.75777.7% of flowCommon StockSEC:0001415889-25-013137:0
Ideal exit: 7 Feb 2026 (T+270)
6,300 shares@ US$13.601820.0% of flowCommon StockSEC:0001415889-25-012768:0
Ideal exit: 3 Feb 2026 (T+270)
528 shares@ US$44.11250.5% of flowCommon StockSEC:0001415889-25-008439:0
Ideal exit: 9 Dec 2025 (T+270)
758 shares@ US$42.66420.7% of flowCommon StockSEC:0001415889-25-007828:0
Ideal exit: 5 Dec 2025 (T+270)
1,335 shares@ US$43.89281.3% of flowCommon StockSEC:0001415889-25-007540:0
Ideal exit: 1 Dec 2025 (T+270)
1,279 shares@ US$45.54861.4% of flowCommon StockSEC:0001415889-25-007260:0
Ideal exit: 29 Nov 2025 (T+270)
115 shares@ US$37.400.1% of flowCommon StockSEC:0001415889-24-023777:0
Ideal exit: 15 Jun 2025 (T+270)
3,927,774 sharesCommon StockSEC:0000950170-24-107530:0
230 shares@ US$41.57830.2% of flowCommon StockSEC:0001415889-24-023154:0
Ideal exit: 3 Jun 2025 (T+270)
10,139 shares0Common StockSEC:0001787306-24-000104:0
21,052 shares@ US$9.5048.4% of flowCommon StockSEC:0001415889-24-007040:0
Ideal exit: 29 Nov 2024 (T+270)
2,910 shares@ US$28.301.9% of flowCommon StockSEC:0001209191-23-055180:0
Ideal exit: 5 Aug 2024 (T+270)
2,625 shares@ US$31.0191.9% of flowCommon StockSEC:0001209191-23-049614:0
Ideal exit: 9 Jun 2024 (T+270)
4,687 shares@ US$30.30243.3% of flowCommon StockSEC:0001209191-23-049292:0
Ideal exit: 7 Jun 2024 (T+270)
147,991 shares@ US$26.2588.7% of flowCommon StockSEC:0001209191-23-048086:0
Ideal exit: 27 May 2024 (T+270)
4,375 shares0Common StockSEC:0001787306-23-000062:0
4,312 shares0Common StockSEC:0001567619-22-012314:0
41,582 shares@ US$16.0050.0% of flowCommon StockSEC:0001567619-21-013730
Ideal exit: 16 Apr 2022 (T+270)
41,582 shares@ US$16.0050.0% of flowCommon StockSEC:0001567619-21-013730:0
Ideal exit: 16 Apr 2022 (T+270)
23 of 23 declarations
About Heron Patrick J
Patrick J. Heron serves as a Director at Imago BioSciences, Inc. and Arcutis Biotherapeutics, Inc. In this role, he contributes to corporate governance and strategic decision-making. His expertise in the biopharmaceutical sector is valuable in guiding development and innovation initiatives within the companies.
